Allergan to acquire Tobira Therapeutics GI R&D pipeline for up to $1.69B: 6 things to know

In an effort to expand its gastroenterology portfolio, Allergan is planning to acquire Tobira Therapeutics for up to $1.69 billion, GEN reports. Here's what you should know.

1. The company is known for its nonalcoholic steatohepatitis and other liver disease therapies. By acquiring Tobira it'll add Cenicriviroc and Evogliptin to its portfolio as well.

2. Allergan CEO Brent Saunders lauded the acquisition saying, "Allergan will now have one of the strongest portfolios of development-stage programs for the treatment of NASH."

3. Allergan also has several other R&D branches, focusing on the central nervous system, eye care, medical aesthetics and dermatology among others.

4. The acquisition still has to gain U.S. antitrust clearance and the company must tender a majority of Tobira's outstanding shares.

5. It's expected the acquisition will close at year's end.

6. Allergan acquired Vitae Pharmaceuticals for $639 million and the purchased of RetroSense Therapeutics for $60 million earlier in the month

More gastroenterology and endoscopy news:
Study: Hepatitis C patients prefer oral dual therapy: 5 takeaways
PA Kristi McClellan joins staff of Penn Highlands Gastroenterology: 3 takeaways
NueHealth, GeneNews partner to offer patients early CRC detection: 3 notes

© Copyright ASC COMMUNICATIONS 2019. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.

 

Top 40 Articles from the Past 6 Months